Cite
HARVARD Citation
Chen, J. et al. (2018). A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (CBCRT01). International journal of cancer. 142 (10), pp. 2130-2138. [Online].